Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 1, 2010, Pages 49-54

  Stevens, Jonathan R ^a   George, Robert A ^b,c   Fusillo, Steven ^a   Stern, Theodore A ^a   Wilens, Timothy E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Mind Matters PC ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; LAMOTRIGINE; LITHIUM; METHYLPHENIDATE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; CARDIOVASCULAR EFFECT; CHILD; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EXTENDED RELEASE FORMULATION; FEMALE; FETAL ALCOHOL SYNDROME; FOOD AND DRUG ADMINISTRATION; HEART RATE; HUMAN; MALE; OPPOSITIONAL DEFIANT DISORDER; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HUMANS; MALE; METHYLPHENIDATE; OSMOTIC PRESSURE; PSYCHIATRIC STATUS RATING SCALES; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77249179312     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.0128     Document Type: Article

References (30)

1. th ed. Washington (DC): American Psychiatric Association, 1994.
2. Arnsten AF: Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 31:2376-2383, 2006.
3. Biederman J, Spencer T, Wilens T: Psychopharmacology: The Essentials of Child and Adolescent Psychopharmacology. Dulcan MK, Weiner JM, eds. Arlington, VA: American Psychiatric Publishing, 635-696, 2006a.
4. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T: A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit=hyperactivity disorder. Biol Psychiatry 59:829-835, 2006b.
5. Camí J, Farré M: Mechanisms of disease. N Engl J Med 349:975-986, 2003.
6. Caplan JP, Epstein LA, Quinn DK, Stevens JR, Stern TA: Neuropsychiatric effects of prescription drug abuse. Neuropsychol Rev 17:363-380, 2007.
7. Daytrana [Package Insert]. Wayne (Pennsylvania): Shire US Inc, 01=08.
8. Findling RL, Short EJ, McNamara NK, Demeter CA, Stansbrey RJ, Gracious BL, Whipkey R, Manos MJ, Calabrese JR: Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit= hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:1445-1453, 2007.
9. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S: American Academy of Child and Adolescent Psychiatry: Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41(2 Suppl):26S-49S, 2002.
10. Klein-Schwartz W: Pediatric methylphenidate exposures: 7-Year experience of poison centers in the United States. Clin Pediatr (Phila) 42:159-164, 2003.
11. Lipkin PH, Butz AM, Cozen MA: High-dose methylphenidate treatment of attention deficit hyperactivity disorder in a preschooler. J Child Adolesc Psychopharmacol 13:103-106, 2003.
12. Markowitz JS, Patrick KS: Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: Does chirality matter? J Clin Psychopharmacol 28(3 Suppl 2):S54-S61, 2008.
13. Markowitz JS, Morton AW, Gaulin BD: Antipsychotic blood concentrations: Nonstandardization of reference ranges. J Clin Psychopharmacol 17:121-124, 1997.
14. Markowitz JS, Straughn AB, Patrick KS: Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: Focus on methylphenidate formulations. Pharmacotherapy 23:1281-1299, 2003a.
15. Markowitz JS, Straughn AB, Patrick KS, DeVane CL, Pestreich L, Lee J, Wang Y, Muniz R: Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet 42:393-401, 2003b.
16. Modi NB, Lam A, Lindemulder E, Wang B, Gupta SK: Application of in vitro-in vivo correlations (IVIVC) in setting formulation release specifications. Biopharm Drug Dispos 21:321-326, 2000.
17. Palumbo DR, Sallee FR, Pelham WE Jr, Bukstein OG, Daviss WB, McDermott MP: Clonidine for attention-deficit=hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 47:180-188, 2008.
18. Patrick KS, Markowtiz JS: Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum Psychopharmacol Clin Exp 12:527-546, 1997.
19. Pawluk LK, Hurwitz TD, Schluter JL, Ullevig C, Mahowald MW: Psychiatric morbidity in narcoleptics on chronic high dose methylphenidate therapy. J Nerv Ment Dis 183:45-48, 1995.
20. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD: Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105, 2001.
21. Pierce D, Dixon CM, Wigal SB, McGough JJ: Pharmacokinetics of methylphenidate transdermal system (MTS): Results from a laboratory classroom study. J Child Adolesc Psychopharmacol 18:355-364, 2008.
22. Pliszka S, AACAP Work Group on Quality Issues: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit= hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894-921, 2007.
23. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group: A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit=hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 114:e206-e216, 2004.
24. Tourette's Syndrome Study Group: Treatment of ADHD in children with tics: A randomized controlled trial. Neurology 58:527-536, 2002.
25. Wilens TE, Spencer TJ: The stimulants revisited. Child Adolesc Psychiatr Clin N Am 9:573-603, 2000.
26. Wilens TE, Spencer T, Biederman J, Wozniak J, Connor D: Combined pharmacotherapy: An emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 34:110-112, 1995.
27. Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, August G, Greenhill L, McBurnett K, Palumbo D, Swanson J, Wolraich M: ADHD treatment with once-daily OROS methylphenidate: Interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psych 42:424-433, 2003.
28. Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M: ADHD treatment with once-daily OROS methylphenidate: Final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 44:1015-1023, 2005.
29. Wolraich ML, Greenhill LL, PelhamW, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G: Randomized controlled trial of OROS methylphenidate once a day in children with attention deficit=hyperactivity disorder. Pediatrics 108:883-892, 2001.
30. Zhu HJ, Wang JS, Donovan JL, Jiang Y, Gibson BB, DeVane CL, Markowitz JS: Interactions of attention-deficit=hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein. Eur J Pharmacol 578:148-158, 2008.